WAYLIVRA

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
IAIN/0023	A.1 - Administrative change - Change in the name and/or address of the MAH	08/11/2022		SmPC, Labelling and PL	
II/0017/G	This was an application for a group of variations.	07/07/2022		SmPC, Labelling and	Update of sections 4.8 and 5.1 of the SmPC to include data from final results of study ISIS 304801 CS7 ('a multicentre

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	C.I.4: Update of sections 4.8 and 5.1 of the SmPC based on the final results from study (ISIS 304801 CS7), a multicentre open label extension study of Volanesorsen administered subcutaneously to patients with Familial Chylomicronemia Syndrome. The Package Leaflet has been updated accordingly. The RMP version 2.2 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the PI in order to align with the QRD template and to introduce minor linguistic update to Annex III of the product information to support product launch. C.I.11b. for RMP: Submission of an updated RMP version 2.2 based on the clinical study report addendum: A randomized, double blind, placebo controlled Phase 3 study of ISIS 304801 administered subcutaneously to patients with Familial Chylomicronemia Syndrome (ISIS 304801 CS6 (APPROACH). C.I.11b. for RMP: Submission of an updated RMP version 2.2 in order to update section V.2 Additional Risk Minimisation Measures in the RMP to reflect a change in the distribution methodology of the educational materials (from a centralised model to a localised model of distribution) and to clarify what is meant by the prescriber kit. C.I.13: Submission of the final report from study ISIS 304801 (CS17). This is a Phase 2/3 double blind, randomized, placebo controlled study, with an			PL	open label extension study of Volanesorsen administered subcutaneously to patients with Familial Chylomicronemia Syndrome'). The Package Leaflet and RMP have been updated accordingly. The MAH took the opportunity to make some editorial changes and bring the PI in line with the latest QRD template.

	open label extension of ISIS 304801 administered subcutaneously to patients with familial partial lipodystrophy. The RMP version 2.2 has also been submitted. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
PSUSA/10762 /202111	Periodic Safety Update EU Single assessment - volanesorsen	10/06/2022	n/a		PRAC Recommendation - maintenance
IB/0020	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	31/03/2022	n/a		
IA/0019/G	This was an application for a group of variations.	21/03/2022	n/a		

	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
R/0016	Renewal of the marketing authorisation.	16/12/2021	14/02/2022		
PSUSA/10762 /202105	Periodic Safety Update EU Single assessment - volanesorsen	02/12/2021	n/a		PRAC Recommendation - maintenance
IB/0015	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	12/10/2021	14/02/2022	SmPC, Annex II, Labelling and PL	
IB/0014	B.II.z - Quality change - Finished product - Other variation	17/09/2021	n/a		
PSUSA/10762 /202011	Periodic Safety Update EU Single assessment - volanesorsen	10/06/2021	n/a		PRAC Recommendation - maintenance
IB/0011/G	This was an application for a group of variations.	25/05/2021	14/02/2022	SmPC, Labelling and	The Product Information includes the following updates: - To include the ATC Code in Section 5.1 of the Summary of

	A.6 - Administrative change - Change in ATC Code/ATC Vet Code B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)			PL	Product Characteristics (SmPC). - To change the shelf-life from '4 years' to '5 years' in section 6.3 of the SmPC. - To introduce editorial changes throughout the product information.
R/0009	Renewal of the marketing authorisation.	10/12/2020	04/02/2021		The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for WAYLIVRA, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.
PSUSA/10762 /202005	Periodic Safety Update EU Single assessment - volanesorsen	26/11/2020	n/a		PRAC Recommendation - maintenance
IA/0008/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.d.1.c - Stability of AS - Change in the re-test	12/10/2020	n/a		

	period/storage period or storage conditions - Change to an approved stability protocol B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol				
IB/0006	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	12/06/2020	n/a		
PSUSA/10762 /201911	Periodic Safety Update EU Single assessment - volanesorsen	11/06/2020	n/a		PRAC Recommendation - maintenance
IB/0005	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	24/04/2020	04/02/2021	SmPC and PL	
R/0003	Renewal of the marketing authorisation.	30/01/2020	16/03/2020		The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for WAYLIVRA, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.
IB/0002	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	18/07/2019	n/a		

IB/0001	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	18/07/2019	16/03/2020	SmPC	